Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Virol ; 93(12): 6818-6821, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34314031

ABSTRACT

Novel coronavirus disease (COVID-19) first described in Wuhan, China in December 2019, has rapidly spread across the world and become a global public health emergency. Literature on the neurological manifestations of COVID-19 is limited. We report a 24-year-old male, who presented with vertigo, dysarthria, and bradyphrenia 3 weeks after being diagnosed with COVID-19 on nasopharyngeal reverse transcription polymerase chain reaction. The patient was diagnosed with acute cerebellitis based on magnetic resonance imaging features and showed improvement posttreatment with intravenous methylprednisone for 5 days. The scope of this article is to highlight the importance of early identification of neurological symptoms and timely management as the outcomes may be catastrophic.


Subject(s)
Brain Diseases/etiology , Brain Diseases/virology , COVID-19/complications , COVID-19/virology , Acute Disease , Adult , Humans , Male , SARS-CoV-2/pathogenicity , Young Adult
2.
J Neuroimmunol ; 353: 577523, 2021 04 15.
Article in English | MEDLINE | ID: mdl-33640717

ABSTRACT

OBJECTIVE: To report a unique case and literature review of post COVID-19 associated transverse myelitis and dysautonomia with abnormal MRI and CSF findings. BACKGROUND: Coronavirus disease have been reported to be associated with several neurological manifestations such as stroke, Guillain-Barré syndrome, meningoencephalitis amongst others. There are only few reported cases of transverse myelitis with the novel coronavirus (n-CoV-2) and only one reported case identifying dysautonomia in COVID-19 patient. Here, we identify a COVID-19 patient diagnosed with acute transverse myelitis in addition to dysautonomia following with complete resolution of symptoms. METHOD: A retrospective chart review of a patient diagnosed with post SARS-CoV-2 infection acute transverse myelitis and dysautonomia, and a review of literature of all the reported cases of transverse myelitis and COVID-19, from December 1st, 2019 till December 25th, 2020, was performed. CONCLUSION: To our knowledge, this is the first reported case of transverse myelitis and dysautonomia in a patient with SARS-CoV-2 infection, who responded to intravenous methyl prednisone and bromocriptine. Follow-up imaging of the spine showed complete resolution of the lesion. Further studies would be recommended to identify the underlying correlation between COVID-19 and transverse myelitis.


Subject(s)
COVID-19/complications , Myelitis, Transverse/virology , Primary Dysautonomias/virology , Spinal Cord/pathology , Adult , Anti-Inflammatory Agents/therapeutic use , Bromocriptine/therapeutic use , COVID-19/pathology , Dopamine Agonists/therapeutic use , Humans , Male , Methylprednisolone/therapeutic use , Myelitis, Transverse/drug therapy , Myelitis, Transverse/pathology , SARS-CoV-2
3.
Elife ; 82019 12 23.
Article in English | MEDLINE | ID: mdl-31868164

ABSTRACT

Myoclonus dystonia (DYT11) is a movement disorder caused by loss-of-function mutations in SGCE and characterized by involuntary jerking and dystonia that frequently improve after drinking alcohol. Existing transgenic mouse models of DYT11 exhibit only mild motor symptoms, possibly due to rodent-specific developmental compensation mechanisms, which have limited the study of neural mechanisms underlying DYT11. To circumvent potential compensation, we used short hairpin RNA (shRNA) to acutely knock down Sgce in the adult mouse and found that this approach produced dystonia and repetitive, myoclonic-like, jerking movements in mice that improved after administration of ethanol. Acute knockdown of Sgce in the cerebellum, but not the basal ganglia, produced motor symptoms, likely due to aberrant cerebellar activity. The acute knockdown model described here reproduces the salient features of DYT11 and provides a platform to study the mechanisms underlying symptoms of the disorder, and to explore potential therapeutic options.


Subject(s)
Dystonic Disorders/genetics , Dystonic Disorders/mortality , Sarcoglycans/genetics , Sarcoglycans/metabolism , Animals , Cerebellar Cortex/metabolism , Cerebellum/metabolism , Cerebellum/pathology , Disease Models, Animal , Dystonia , Dystonic Disorders/chemically induced , Dystonic Disorders/pathology , Ethanol/adverse effects , Female , Ganglia/metabolism , Genetic Predisposition to Disease/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , RNA, Small Interfering
SELECTION OF CITATIONS
SEARCH DETAIL
...